



16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024

American Diabetes Association
Professional Practice Committee*

Diabetes Care 2024;47(Suppl. 1):S295–S306 | <https://doi.org/10.2337/dc24-S016>

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Among hospitalized individuals, hyperglycemia, hypoglycemia, and glucose variability are associated with adverse outcomes, including increased morbidity and mortality (1). Identification and careful management of people with diabetes and dysglycemia during hospitalization has direct and immediate benefits. Diabetes management in the inpatient setting is facilitated by identification and treatment of hyperglycemia prior to elective procedures, a dedicated inpatient diabetes management service applying validated standards of care, and a proactive transition plan for outpatient diabetes care with timely prearranged follow-up appointments. These steps can improve outcomes, shorten hospital stays, and reduce the need for readmission and emergency department visits. For older hospitalized individuals or for people with diabetes in long-term care facilities, please see Section 13, “Older Adults.”

HOSPITAL CARE DELIVERY STANDARDS

Recommendations

16.1 Perform an A1C test on all people with diabetes or hyperglycemia (random blood glucose >140 mg/dL [>7.8 mmol/L]) admitted to the hospital if no A1C test result is available from the prior 3 months. **B**

16.2 Institutions should implement protocols using validated written or computerized provider order entry sets for management of dysglycemia in the hospital (including emergency department, intensive care unit [ICU] and non-ICU wards, gynecology-obstetrics/delivery units, dialysis suites, and behavioral health units) that allow for a personalized approach, including glucose monitoring, insulin and/or noninsulin therapy, hypoglycemia management, diabetes self-management education, nutrition recommendations, and transitions of care. **B**

Considerations on Admission

High-quality hospital care for diabetes requires standards for care delivery, which are best implemented using structured order sets and quality improvement strategies for

*A complete list of members of the American Diabetes Association Professional Practice Committee can be found at <https://doi.org/10.2337/dc24-S1NT>.

Duality of interest information for each author is available at <https://doi.org/10.2337/dc24-SDIS>.

Suggested citation: American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: Standards of Care in Diabetes—2024. *Diabetes Care* 2024;47(Suppl. 1):S295–S306

© 2023 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/journals/pages/license>.

process improvement. Unfortunately, “best practice” protocols, reviews, and guidelines are inconsistently implemented within hospitals (2). To correct this, medical centers striving for optimal inpatient diabetes treatment should establish protocols and structured order sets, which include computerized provider order entry (CPOE). Institutions are encouraged to perform audits regularly to monitor proper use and institute educational/training programs to keep staff up to date.

Initial evaluation should state the type of diabetes (i.e., type 1, type 2, gestational, pancreatogenic, drug related, or nutrition related) when it is known. Because inpatient treatment and discharge planning are more effective when preadmission glycemia is considered, A1C should be measured for all people with diabetes or dysglycemia admitted to the hospital if no A1C test result is available from the previous 3 months (3–6). In addition, diabetes self-management knowledge and behaviors should be assessed on admission, and diabetes self-management education provided (if available), especially if a new treatment plan is being considered. Diabetes self-management education should include knowledge and survival skills needed after discharge, such as medication dosing and administration, glucose monitoring, and recognition and treatment of hypoglycemia (7). Evidence supports preadmission treatment of hyperglycemia in people scheduled for elective surgery as an effective means of reducing adverse outcomes (8–11).

The National Academy of Medicine recommends CPOE to prevent medication-related errors and to increase medication administration efficiency (12). Systematic reviews of randomized controlled trials using computerized advice to improve glycemic outcomes in the hospital found significant improvement in the percentage of time individuals spent in the glycemic goal range, lower mean blood glucose levels, and no increase in hypoglycemia (13). Where feasible, there should be structured order sets that provide computerized guidance for glycemic management. Insulin dosing algorithms using machine learning and data in the electronic health record (EHR) currently in development show promise for predicting insulin requirements during hospitalization (14).

Diabetes Care Specialists in the Hospital

Recommendation

16.3 When caring for hospitalized people with diabetes (with an existing or new diagnosis) or stress hyperglycemia, consult with a specialized diabetes or glucose management team when accessible. **B**

Care provided by appropriately trained specialists or specialty teams may reduce the length of stay and improve glycemic and other clinical outcomes (15,16). In addition, the increased risk of 30-day readmission following hospitalization that has been attributed to diabetes can be reduced, and costs saved, when inpatient care is provided by a specialized diabetes management team (15,17,18). In a cross-sectional study comparing usual care to specialists reviewing diabetes cases and making recommendations virtually through the EHR, rates of both hyperglycemia and hypoglycemia were reduced by 30–40% (19). Providing inpatient diabetes self-management education and developing a diabetes discharge plan that includes continued access to diabetes medications and supplies and ongoing education and support are key strategies to improve outcomes (20,21). Details of diabetes care team composition and other resources are available from the Joint Commission accreditation program for the hospital care of diabetes, from the Society of Hospital Medicine workbook, and from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group (22–24).

GLYCEMIC GOALS IN HOSPITALIZED ADULTS

Recommendations

16.4 Insulin **A** and/or other therapies **B** should be initiated or intensified for treatment of persistent hyperglycemia starting at a threshold of ≥ 180 mg/dL (≥ 10.0 mmol/L) (confirmed on two occasions within 24 h) for noncritically ill (non-ICU) individuals. **A**

16.5a Once therapy is initiated, a glycemic goal of 140–180 mg/dL (7.8–10.0 mmol/L) is recommended for most critically ill (ICU) individuals with hyperglycemia. **A**

16.5b More stringent glycemic goals, such as 110–140 mg/dL (6.1–7.8 mmol/L), may be appropriate for selected

critically ill individuals and are acceptable if they can be achieved without significant hypoglycemia. **B**

Standard Definitions of Glucose Abnormalities

Hyperglycemia in hospitalized individuals is defined as blood glucose levels > 140 mg/dL (> 7.8 mmol/L) (2). An admission A1C value $\geq 6.5\%$ (≥ 48 mmol/mol) suggests that the onset of diabetes preceded hospitalization (see Section 2, “Diagnosis and Classification of Diabetes”). Level 1 hypoglycemia is defined as a glucose concentration of 54–69 mg/dL (3.0–3.8 mmol/L). Level 2 hypoglycemia is defined as a glucose concentration < 54 mg/dL (< 3.0 mmol/L), which is typically the threshold for neuroglycopenic symptoms. Level 3 hypoglycemia is defined as a clinical event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery (Table 6.4) (25,26). Levels 2 and 3 require immediate intervention and correction of low blood glucose. Prompt treatment of level 1 hypoglycemia is recommended as an effort to prevent progression to more significant level 2 and level 3 hypoglycemia.

Glycemic Goals

In a landmark clinical trial conducted in a surgical intensive care unit (ICU), Van den Berghe et al. (27) demonstrated that an intensive intravenous insulin protocol with a glycemic goal of 80–110 mg/dL (4.4–6.1 mmol/L) reduced mortality by 40% compared with a standard approach of a glycemic goal of 180–215 mg/dL (10–12 mmol/L) in critically ill hospitalized individuals with recent surgery. This study provided evidence that active treatment to lower blood glucose in hospitalized individuals could have immediate benefits. However, a large, multicenter follow-up study in critically ill hospitalized individuals, the Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial (28), led to a reconsideration of the optimal glucose lowering goal in critical illness. In this trial, critically ill individuals randomized to intensive glycemic management (80–110 mg/dL [4.4–6.1 mmol/L]) derived no significant treatment advantage compared with a group with more moderate glycemic goals (140–180 mg/dL [7.8–10.0 mmol/L]) and had slightly but

significantly higher mortality (27.5% vs. 25%). The intensively treated group had 10- to 15-fold greater rates of hypoglycemia, which may have contributed to the adverse outcomes noted. The findings from the NICE-SUGAR trial, supported by several meta-analyses and a randomized controlled trial, showed higher rates of hypoglycemia and an increase in mortality with more aggressive glycemic management goals compared with moderate glycemic goals (29–31). Based on these results, insulin and/or other therapies should be initiated for the treatment of persistent hyperglycemia ≥ 180 mg/dL (≥ 10.0 mmol/L). Once therapy is initiated, a glycemic goal of 140–180 mg/dL (7.8–10.0 mmol/L) is recommended for most critically ill individuals with hyperglycemia. Although not as well supported by data from randomized controlled trials, these recommendations have been extended to hospitalized individuals without critical illness. More stringent glycemic goals, such as 110–140 mg/dL (6.1–7.8 mmol/L), may be appropriate for selected individuals (e.g., critically ill individuals undergoing surgery) if it can be achieved without significant hypoglycemia (32,33).

For inpatient management of hyperglycemia in noncritical care settings, a glycemic goal of 100–180 mg/dL (5.6–10.0 mmol/L) is recommended, whether it is new hyperglycemia (e.g., newly diagnosed diabetes or stress hyperglycemia) or hyperglycemia related to diabetes prior to admission (2). It has been found that fasting glucose levels < 100 mg/dL (< 5.6 mmol/L) are predictors of hypoglycemia within the next 24 h (34). Glycemic levels up to 250 mg/dL (13.9 mmol/L) may be acceptable in selected populations (terminally ill individuals with short life expectancy, advanced kidney failure [and/or on dialysis], high risk for hypoglycemia, and/or labile glycemic excursions). In these individuals, less aggressive treatment goals that would help avoid symptomatic hypoglycemia and/or hyperglycemia are often appropriate. Clinical judgment combined with ongoing assessment of clinical status, including changes in the trajectory of glucose measures, illness severity, nutritional status, or concomitant medications that might affect glucose levels (e.g., glucocorticoids), may be incorporated into the day-to-day decisions regarding treatment dosing.

GLUCOSE MONITORING

In hospitalized individuals with diabetes who are eating, point-of-care (POC) blood glucose monitoring should be performed before meals; in those not eating, glucose monitoring is advised every 4–6 h (26). More frequent POC blood glucose monitoring ranging from every 30 min to every 2 h is the required standard for safe use of intravenous insulin therapy.

Hospital blood glucose monitoring should be performed with U.S. Food and Drug Administration (FDA)–approved POC hospital-calibrated glucose monitoring systems (35). POC blood glucose meters are not as accurate or as precise as laboratory glucose analyzers, and capillary blood glucose readings are subject to artifacts due to perfusion, edema, anemia/erythrocytosis, and several medications commonly used in the hospital (35) (Table 7.1). The FDA has established standards for capillary (finger-stick) POC glucose monitoring in the hospital (35). The balance between analytic requirements (e.g., accuracy, precision, and interference) and clinical requirements (e.g., rapidity, simplicity, and POC) has not been uniformly resolved (35–38), and most hospitals have arrived at their own policies to balance these parameters. It is critically important that devices selected for in-hospital use, and the workflow through which they are applied, undergo careful analysis of performance and reliability and ongoing quality assessments (38). Recent studies indicate that POC measures provide adequate information for usual practice, with only rare instances where care has been compromised (36,37). Best practice dictates that any glucose result that does not correlate with the individual's clinical status should be confirmed by measuring a sample in the clinical laboratory, particularly for asymptomatic hypoglycemic events.

Continuous Glucose Monitoring

Recommendations

16.6 In people with diabetes using a personal continuous glucose monitoring (CGM) device, the use of CGM should be continued during hospitalization if clinically appropriate, with confirmatory point-of-care (POC) glucose measurements for insulin dosing decisions and hypoglycemia assessment, if resources and training are available, and according to an institutional protocol. **B**

16.7 For people with diabetes using an automated insulin delivery (AID) system along with CGM, the use of AID and CGM should be continued during hospitalization if clinically appropriate, with confirmatory POC blood glucose measurements for insulin dosing decisions and hypoglycemia assessment, if resources and training are available, and according to an institutional protocol. **C**

Several studies have demonstrated that inpatient use of continuous glucose monitoring (CGM) has advantages over POC glucose monitoring in detecting hypoglycemia, particularly nocturnal, prolonged and/or asymptomatic hypoglycemia (39–41), and in reducing recurrent hypoglycemia (42,43). However, at this time, initiating use of a new CGM device has not been approved by the FDA. During the coronavirus disease 2019 (COVID-19) pandemic, many institutions used CGM in ICU and non-ICU settings, with the aim of minimizing exposure time and saving personal protective equipment, under an FDA policy of enforcement discretion (44,45). Data on the safety and efficacy of real-time CGM use in the hospital, particularly with implementation of remote monitoring (e.g., a glucose telemetry system), is growing (42,43,45–50).

Continuation of personal CGM device use, particularly for people with type 1 or type 2 diabetes treated with intensive therapy at increased risk for hypoglycemia during hospitalization, is recommended. Confirmatory POC capillary glucose testing, using hospital-calibrated glucose meters, is recommended for insulin dosing and hypoglycemia assessment (e.g., hybrid testing protocols) (51). People with diabetes should be counseled about meaningful use of trend arrows and alarms and about notifying nursing staff for confirmation of these events with POC capillary glucose testing. Similarly, continuation of AID systems should be supported during hospitalization, when clinically appropriate, and with proper staff training and supervision (41,45). Observational studies have demonstrated improvements in patient satisfaction and improved detection of glycemic excursions (40,47). If the reason for admission is suspected to be related to device malfunction or lack of adequate education/training or use, consultation with the endocrinology/

diabetes care team or diabetes care and education specialists, if available, is recommended. Hospitals are encouraged to develop institutional policies and have trained personnel with knowledge of diabetes technology. Recent review articles provide details on accuracy, interferences, precautions, and contraindications of diabetes technology devices in the hospital setting (50,51).

For more information on CGM, see Section 7, "Diabetes Technology."

GLUCOSE-LOWERING TREATMENT IN HOSPITALIZED PATIENTS

An individualized approach for glycemic management is encouraged throughout the hospital stay and should take into consideration several predictive factors for achieving glycemic goals, such as prior home use and dose of insulin or noninsulin therapy, expected level of insulin resistance, prior A1C, current glucose levels, oral intake, and duration of diabetes.

Insulin Therapy

Recommendations

16.8 Basal insulin or a basal plus bolus correction insulin plan is the preferred treatment for noncritically ill hospitalized individuals with poor oral intake or those who are taking nothing by mouth. **A**

16.9 An insulin plan with basal, prandial, and correction components is the preferred treatment for most noncritically ill hospitalized individuals with adequate nutritional intake. **A**

16.10 Sole use of a correction or supplemental insulin without basal insulin (formerly referred to as a sliding scale) in the inpatient setting is discouraged. **A**

Critical Care Setting

Continuous intravenous insulin infusion is the most effective method for achieving specific glycemic goals and avoiding hypoglycemia in the critical care setting. Intravenous insulin infusions should be administered using validated written or computerized protocols that allow for predefined adjustments in the insulin infusion rate based on glycemic fluctuations and immediate past and current insulin infusion rates (52). For diabetic ketoacidosis (DKA) and hyperglycemic

hyperosmolar state (HHS) management, continuous intravenous insulin infusion is given for correction of hyperglycemia, hyperketonemia, and acid-base disorder following a fixed-rate intravenous insulin infusion (53) or nurse-driven protocol with a variable rate based on glucose values (54). Individuals with mild and uncomplicated DKA can be managed with subcutaneous rapid-acting insulin doses given every 1–2 h (55).

Noncritical Care Setting

In most instances, insulin is the preferred treatment for hyperglycemia in hospitalized individuals. In certain circumstances, it may be appropriate to continue home oral glucose-lowering medications, such as dipeptidyl peptidase 4 inhibitors (DPP-4i) (52,56). If oral medications are held in the hospital but will be reinstated after discharge, there should be a protocol for guiding resumption of home medications 1–2 days prior to discharge. For people taking insulin, several reports indicate that inpatient use of insulin pens is safe and may improve nurse satisfaction when safety protocols, including nursing education, are in place to guarantee single-person use (57–61).

Outside of critical care units, scheduled subcutaneous insulin orders are recommended for the management of hyperglycemia in people with diabetes and hyperglycemia. Use of insulin analogs or human insulin results in similar glycemic outcomes in the hospital setting but may increase severe hypoglycemic events (62). The use of subcutaneous rapid- or short-acting insulin before meals, or every 4–6 h if no meals are given or if the individual is receiving continuous enteral/parenteral nutrition, is indicated to correct or prevent hyperglycemia. Basal insulin, or a basal plus bolus correction schedule, is the preferred treatment for noncritically ill hospitalized individuals with inadequate or restricted oral intake. An insulin schedule with basal, prandial, and correction components is the preferred treatment for most noncritically ill hospitalized people with diabetes with adequate nutritional intake.

A randomized controlled trial has shown that basal plus bolus treatment improved glycemic outcomes and reduced hospital complications compared with a correction or supplemental insulin without basal insulin (formerly known as sliding scale) for people with type 2 diabetes admitted for general surgery (63). Prolonged use of

correction or supplemental insulin without basal insulin as the sole treatment of hyperglycemia is strongly discouraged in the inpatient setting, with the exception of people with type 2 diabetes in noncritical care with mild hyperglycemia (2,64,65).

A prospective randomized inpatient study of 70/30 intermediate-acting (NPH)/regular insulin mixture versus basal-bolus therapy showed comparable glycemic outcomes but significantly increased hypoglycemia in the group receiving insulin mixture (66). Therefore, insulin mixtures such as 75/25, 70/30, or 50/50 insulins are not routinely recommended for in-hospital use.

Data on the use of glargine U-300 and degludec U-100 or U-200 in the inpatient and perioperative settings are limited. A few studies have shown that they demonstrated similar efficacy and safety compared with glargine U-100 (67–69). At this time, there is no available evidence for weekly insulin use in hospital or surgical settings.

Type 1 Diabetes

For people with type 1 diabetes, dosing insulin based solely on premeal glucose levels does not account for basal insulin requirements or caloric intake, increasing the risk of both hypoglycemia and hyperglycemia. Typically, basal insulin dosing is based on body weight and expected sensitivity to insulin, with some evidence that people with renal insufficiency should be treated with lower insulin doses (70,71). An insulin schedule with basal and correction components is necessary for all hospitalized individuals with type 1 diabetes, even when taking nothing by mouth, with the addition of prandial insulin when eating. Policies and best practice alerts in the EHR should be put in place to ensure that basal insulin (given subcutaneously, via insulin pump or by insulin infusion) is not held for people with type 1 diabetes, especially during care transitions, and that ongoing prescriber and nursing education is provided (60).

Transitioning From Intravenous to Subcutaneous Insulin

When discontinuing intravenous insulin, a transition protocol is recommended, as it is associated with less morbidity and lower costs of care. Subcutaneous basal insulin should be given 2 h before intravenous infusion is discontinued, with the aim of minimizing rebound hyperglycemia (2,72,73).

Emerging data from several studies show that the administration of a low dose (0.15–0.3 units/kg) of basal insulin analog in addition to intravenous insulin infusion may reduce the duration of insulin infusion and length of hospital stay and prevent rebound hyperglycemia without increased risk of hypoglycemia (74–76).

For transitioning, the total daily dose of subcutaneous insulin can be calculated based on the insulin infusion rate during the prior 6–8 h when stable glycemic goals were achieved, based on prior home insulin dose, or following a weight-based approach (72,73). For people being transitioned to concentrated insulin (U-200, U-300, or U-500) in the inpatient setting, it is important to ensure correct dosing by using a separate pen or vial for each person and by meticulous pharmacy and nursing supervision of the dose administered (77,78).

Noninsulin Therapies

Recommendation

16.11 For people with type 2 diabetes hospitalized with heart failure, it is recommended that use of a sodium–glucose cotransporter 2 inhibitor be initiated or continued during hospitalization and upon discharge, if there are no contraindications and after recovery from the acute illness. **A**

The safety and efficacy of noninsulin glucose-lowering therapies in the hospital setting has expanded recently (79–83). A randomized trial and an observational study have demonstrated the safety and efficacy of DPP-4i in specific groups of hospitalized people with diabetes (84,85). The use of DPP-4i with or without basal insulin may be a safer and simpler plan for people with mild to moderate hyperglycemia on admission (e.g., admission glucose <180–200 mg/dL), with reduced risk of hypoglycemia (79,85,86). Of note, the FDA states that health care professionals should consider discontinuing saxagliptin and alogliptin in people who develop heart failure (87). Data on the inpatient use of glucagon-like peptide 1 (GLP-1) receptor agonists are still mostly limited to research studies and select populations that are medically stable (83).

For people with type 2 diabetes hospitalized with heart failure, it is recommended that use of a sodium–glucose cotransporter 2 (SGLT2) inhibitor be initiated or continued during hospitalization and upon discharge,

if there are no contraindications and after recovery from the acute illness (88,89). SGLT2 inhibitors should be avoided in cases of severe illness, in people with ketonemia or ketonuria, and during prolonged fasting and surgical procedures (90–93). Proactive adjustment of diuretic dosing is recommended during hospitalization and/or discharge, especially in collaboration with a cardiology/heart failure consult team (90–93). The FDA has warned that SGLT2 inhibitors should be stopped 3 days before scheduled surgeries (4 days in the case of ertugliflozin) (94).

HYPOGLYCEMIA

Recommendations

16.12 A hypoglycemia management protocol should be adopted and implemented by each hospital or hospital system. A plan for preventing and treating hypoglycemia should be established for each individual. Episodes of hypoglycemia in the hospital should be documented in the electronic health record and tracked for quality assessment and quality improvement. **E**

16.13 Treatment plans should be reviewed and changed as necessary to prevent hypoglycemia and recurrent hypoglycemia when a blood glucose value of <70 mg/dL (<3.9 mmol/L) is documented. **C**

People with or without diabetes may experience hypoglycemia in the hospital setting. While hypoglycemia is associated with increased mortality (95,96), in many cases, it is a marker of an underlying disease rather than the cause of fatality. However, hypoglycemia is a severe consequence of dysregulated metabolism and/or diabetes treatment, and it is imperative that it be minimized during hospitalization. Many episodes of inpatient hypoglycemia are preventable. A hypoglycemia prevention and management protocol should be adopted and implemented by each hospital or hospital system. A standardized hospital-wide, nurse-initiated hypoglycemia treatment protocol should be in place to immediately address blood glucose levels <70 mg/dL (<3.9 mmol/L) (97,98). In addition, individualized plans for preventing and treating hypoglycemia for each individual should also be developed. An American Diabetes Association consensus statement recommends that an individual's treatment

plan be reviewed any time a blood glucose value of <70 mg/dL (<3.9 mmol/L) occurs, as this level often predicts subsequent level 3 hypoglycemia (99). Episodes of hypoglycemia in the hospital should be documented in the EHR and tracked (1). A key strategy is embedding hypoglycemia treatment into all insulin and insulin infusion orders.

Inpatient Hypoglycemia: Risk Factors, Treatment, and Prevention

Insulin is one of the most common medications causing adverse events in hospitalized individuals. Errors in insulin dosing, missed doses, and/or administration errors including incorrect insulin type and incorrect timing of dose occur relatively frequently (100–102) and include prescriber (ordering), pharmacy (dispensing), and nursing (administration) errors. Common preventable sources of iatrogenic hypoglycemia are improper prescribing of other glucose-lowering medications and inappropriate management and follow-up of the first episode of hypoglycemia (103). Kidney failure is an important risk factor for hypoglycemia in the hospital (104), possibly as a result of decreased insulin clearance. Studies of “bundled” preventive therapies, including proactive surveillance of glycemic outliers and an interdisciplinary data-driven approach to glycemic management, showed that hypoglycemic episodes in the hospital could be reduced or prevented. Compared with baseline, studies found that hypoglycemic events decreased by 56–80% (98,105,106). The Joint Commission, a global quality improvement and patient safety in health care organization, recommends that all hypoglycemic episodes be evaluated for a root cause and the episodes be aggregated and reviewed to address systemic issues (23).

In addition to errors with insulin treatment, iatrogenic hypoglycemia may be induced by a sudden reduction of corticosteroid dose, reduced oral intake, emesis, inappropriate timing of short- or rapid-acting insulin doses in relation to meals, reduced infusion rate of intravenous dextrose, unexpected interruption of enteral or parenteral feedings, delayed or missed blood glucose checks, and altered ability of the individual to report symptoms (107).

Recent inpatient studies show promise for CGM as an early warning system to alert of impending hypoglycemia, offering an opportunity to mitigate it before it happens (46–49). The use of personal CGM and AID devices, such as insulin pumps

that can automatically deliver correction doses and change basal delivery rates in real time, should be supported for ongoing use during hospitalization for individuals who are capable of using their devices safely and independently when proper oversight supervision is available. Hospitals should be encouraged to develop policies and protocols to support inpatient use of individual- and hospital-owned diabetes technology and have expert staff available for safe implementation and evaluation of continued use during the hospital stay (51). Hospital information technology teams are beginning to integrate CGM data into the EHR. The ability to download and interpret diabetes device data during hospitalization can inform insulin dosing during hospitalization and care transitions (41).

For more information on CGM, see Section 7, "Diabetes Technology."

Predictors of Hypoglycemia

In people with diabetes, it is well established that an episode of severe hypoglycemia increases the risk for a subsequent event, partly because of impaired counterregulation (108,109). In a study of hospitalized individuals, 84% of people who had an episode of severe hypoglycemia (defined as <40 mg/dL [<2.2 mmol/L]) had a preceding episode of hypoglycemia (<70 mg/dL [<3.9 mmol/L]) during the same admission (110). In another study of hypoglycemic episodes (defined as <50 mg/dL [<2.8 mmol/L]), 78% of individuals were taking basal insulin, with the incidence of hypoglycemia peaking between midnight and 6:00 A.M. Despite recognition of hypoglycemia, 75% of individuals did not have their dose of basal insulin changed before the next basal insulin administration (111).

Recently, several groups have developed algorithms to predict episodes of hypoglycemia in the inpatient setting (112,113). Models such as these are potentially important and, once validated for general use, could provide a valuable tool to reduce rates of hypoglycemia in the hospital. In one retrospective cohort study, a fasting blood glucose of <100 mg/dL was shown to be a predictor of next-day hypoglycemia (34).

MEDICAL NUTRITION THERAPY IN THE HOSPITAL

The goals of medical nutrition therapy in the hospital are to provide adequate

calories to meet metabolic demands, optimize glycemic outcomes, address personal food preferences, and facilitate the creation of a discharge plan. The American Diabetes Association does not endorse any single meal plan or specified percentages of macronutrients. Current nutrition recommendations advise individualization based on treatment goals, physiological parameters, and medication use. Controlled carbohydrate meal plans, where the amount of carbohydrate on each meal tray is calculated, are preferred by many hospitals, as they facilitate matching the prandial insulin dose to the amount of carbohydrate given (114). Orders should also indicate that the meal delivery and nutritional insulin coverage should be coordinated, as their variability often creates the possibility of hyperglycemic and hypoglycemic events (20). Some hospitals offer "meals on demand," where individuals may order meals from the menu at any time during the day. This option improves patient satisfaction but complicates insulin-meal coordination and can lead to insulin stacking if meals are too close together. Finally, if the hospital food service supports carbohydrate counting, this option should be made available to people with diabetes counting carbohydrates at home and people wearing insulin pumps (115,116).

SELF-MANAGEMENT IN THE HOSPITAL

Diabetes self-management in the hospital may be appropriate for specific individuals who wish to continue to perform self-care while acutely ill (117–119). Candidates include children with parental supervision, adolescents, and adults who successfully perform diabetes self-management at home and whose cognitive and physical skills needed to successfully self-administer insulin and perform glucose monitoring are not compromised (7,41). In addition, they should have adequate oral intake, be proficient in carbohydrate estimation, take multiple daily insulin injections or wear insulin pumps, have stable insulin requirements, and understand sick-day management. If self-management is supported, a policy should include a requirement that people with diabetes and the care team agree that self-management is appropriate on a daily basis during hospitalization. Hospital personal medication policies may include guidance for people with diabetes who

wish to take their own or hospital-dispensed insulin and noninsulin injectable medications during their hospital stay. A hospital policy for personal medication may consider a pharmacy exception on a case-by-case basis along with the care team. Pharmacy must verify any home medication and require a prescriber order for the individual to self-administer home or hospital-dispensed medication under the supervision of the registered nurse. If an insulin pump or CGM device is worn, hospital policy and procedures delineating guidelines for wearing an insulin pump and/or CGM device should be developed according to consensus guidelines, including the changing of insulin infusion sites and CGM glucose sensors (41,120,121). As outlined in Recommendations 7.33 and 7.34, people with diabetes wearing diabetes devices should be supported to continue them in an inpatient setting if they are assessed and deemed competent to perform self-care and proper supervision is available.

STANDARDS FOR SPECIAL SITUATIONS

Enteral/Parenteral Feedings

For individuals receiving enteral or parenteral feedings who require insulin, the insulin orders should include coverage of basal, prandial, and correctional needs (115,122,123). It is essential that people with type 1 diabetes continue to receive basal insulin even if feedings are discontinued.

Most adults receiving basal insulin should continue with their basal dose, while the insulin dose for the total daily nutritional component may be calculated as 1 unit of insulin for every 10–15 g of carbohydrate in the enteral and parenteral formulas. Commercially available cans of enteral nutrition contain variable amounts of carbohydrates and may be infused at different rates.

All of this must be considered when calculating insulin doses to cover the nutritional component of enteral nutrition (116). Giving NPH insulin two or three times daily (every 8 or 12 h) to cover individual requirements is a reasonable option. Adjustments in insulin doses should be made frequently. Correctional insulin should also be administered subcutaneously every 6 h with regular human insulin. If enteral nutrition is interrupted, a dextrose infusion should be started immediately to prevent hypoglycemia and

to allow time to determine more appropriate insulin doses.

For adults receiving enteral bolus feedings, approximately 1 unit of regular human insulin or rapid-acting insulin per every 10–15 g of carbohydrate should be given subcutaneously before each feeding. To mitigate any hyperglycemia, correctional insulin should be added as needed before each feeding.

In individuals receiving nocturnal tube feeding, NPH insulin administered along with the initiation of the feeding is a reasonable approach to cover this nutritional load.

For individuals receiving continuous peripheral or central parenteral nutrition, human regular insulin may be added to the solution, particularly if >20 units of correctional insulin have been required in the past 24 h. A starting dose of 1 unit of regular human insulin for every 10 g of dextrose has been recommended (105) and should be adjusted daily in the solution. Adding insulin to the parenteral nutrition bag is the safest way to prevent hypoglycemia if the parenteral nutrition is stopped or interrupted. Correctional insulin should be administered subcutaneously to address any hyperglycemia.

Because continuous enteral or parenteral nutrition results in a continuous postprandial state, efforts to bring blood glucose levels to below 140 mg/dL (7.8 mmol/L) substantially increase the risk of hypoglycemia in these individuals. For full enteral/parenteral feeding guidance, please refer to randomized controlled trials detailing this topic (122,124).

Glucocorticoid Therapy

The prevalence of consistent use of glucocorticoid therapy in hospitalized individuals can approach 10–15%, and these medications can induce hyperglycemia in 56–86% of these individuals with and without preexisting diabetes (125–127). If left untreated, this hyperglycemia increases mortality and morbidity risk, e.g., infections and cardiovascular events. Glucocorticoid type and duration of action must be considered in determining appropriate insulin treatments. Daily-ingested intermediate-acting glucocorticoids such as prednisone reach peak plasma levels in 4–6 h (128) but have pharmacologic actions that can last throughout the day. Individuals placed on morning steroid therapy have disproportionate hyperglycemia during the day

but frequently reach blood glucose goals overnight regardless of treatment (125). In individuals on once- or twice-daily steroids, administering NPH insulin is a standard approach. NPH is usually administered in addition to daily basal-bolus insulin or in addition to oral glucose-lowering medications, depending on the type of diabetes and recent diabetes medication prior to starting steroids. Because NPH action peaks about 4–6 h after administration, it is recommended that it be administered concomitantly with intermediate-acting steroids (129). For long-acting glucocorticoids such as dexamethasone and multi-dose or continuous glucocorticoid use, long-acting basal insulin may be required to manage fasting blood glucose levels (53,130). For higher doses of glucocorticoids, increasing doses of prandial (if eating) and correction insulin, sometimes as much as 40–60% or more, are often needed in addition to basal insulin (131,132). A retrospective study found that increasing the ratio of insulin to steroids was positively associated with improved time in range (70–180 mg/dL); however, there was an increase in hypoglycemia (133). If insulin orders are initiated, daily adjustments based on levels of glycemia and anticipated changes in type, dosages, and duration of glucocorticoids, along with POC blood glucose monitoring, are critical to reducing hypoglycemia and hyperglycemia.

Perioperative Care

It is estimated that up to 20% of individuals undergoing general surgery have diabetes, and 23–60% have prediabetes or undiagnosed diabetes. Surgical stress and counterregulatory hormone release increase the risk of hyperglycemia as well as mortality, infection, and length of stay (134–136). There are little data available to guide care of people with diabetes through the perioperative period. To reduce surgical risk in people with diabetes, some institutions (135,137,138) have A1C cutoffs for elective surgeries, and some have developed optimization programs to lower A1C prior to surgery (134,135,137,138).

The following approach (134,135,137) may be considered:

1. A preoperative risk assessment should be performed for people with diabetes who are at high risk for ischemic

heart disease and those with autonomic neuropathy or renal failure.

2. The A1C goal for elective surgeries should be <8% (<63.9 mmol/L) whenever possible.
3. The blood glucose goal in the perioperative period should be 100–180 mg/dL (5.6–10.0 mmol/L) (135) within 4 h of the surgery. CGM should not be used alone for glucose monitoring during surgery (138).
4. Metformin should be held on the day of surgery.
5. SGLT2 inhibitors should be discontinued 3–4 days before surgery.
6. Hold other oral glucose-lowering agents the morning of surgery or procedure and give one-half of NPH dose or 75–80% doses of long-acting analog insulin or adjust insulin pump basal rates based on the type of diabetes and clinical judgment.
7. Monitor blood glucose at least every 2–4 h while the individual takes nothing by mouth and dose with short- or rapid-acting insulin as needed.
8. There are little data on the safe use and/or influence of GLP-1 receptor agonists on glycemia and delayed gastric emptying in the perioperative period.
9. Stricter perioperative glycemic goals are not advised, as perioperative glycemic goals stricter than 80–180 mg/dL (4.4–10.0 mmol/L) may not improve outcomes and are associated with more hypoglycemia (137).
10. Compared with usual dosing, a reduction by 25% of basal insulin given the evening before surgery is more likely to achieve perioperative blood glucose goals with a lower risk for hypoglycemia (139).
11. In individuals undergoing noncardiac general surgery, basal insulin plus premeal short- or rapid-acting insulin (basal-bolus) coverage has been associated with improved glycemic outcomes and lower rates of perioperative complications compared with the reactive, correction-only short- or rapid-acting insulin coverage alone with no basal insulin dosing (63,134,135).

Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State

There is considerable variability in the presentation of DKA and HHS, ranging from euglycemia or mild hyperglycemia and acidosis to severe hyperglycemia,

dehydration, and coma; therefore, individualization of treatment based on a careful clinical and laboratory assessment is needed (75,140–142).

Management goals include restoration of circulatory volume and tissue perfusion, resolution of ketoacidosis, and correction of electrolyte imbalance and acidosis. It is also essential to treat any correctable underlying cause of DKA, such as sepsis, myocardial infarction, or stroke. In critically ill and mentally obtunded individuals with DKA or HHS, continuous intravenous insulin is the standard of care. Successful transition from intravenous to subcutaneous insulin requires administration of basal insulin 2–4 h before the intravenous insulin is stopped to prevent recurrence of ketoacidosis and rebound hyperglycemia (72,73,140). Recent studies have reported that the administration of a low dose of basal insulin analog in addition to intravenous insulin infusion may prevent rebound hyperglycemia without increased risk of hypoglycemia (74–76,140). There is no significant difference in outcomes for intravenous human regular insulin versus subcutaneous rapid-acting analogs when combined with aggressive fluid management for treating mild or moderate DKA (143). Individuals with uncomplicated DKA may sometimes be treated with subcutaneous rapid-acting insulin analogs in the emergency department or step-down units (144). This approach may be safer and more cost-effective than treatment with intravenous insulin. If subcutaneous insulin administration is used, it is important to provide an adequate fluid replacement, frequent POC blood glucose monitoring, treatment of any concurrent infections, and appropriate follow-up to avoid recurrent DKA. Several studies have shown that the use of bicarbonate in people with DKA made no difference in the resolution of acidosis or time to discharge, and its use is generally not recommended (145). For further treatment information, refer to recent in-depth reviews (53, 107,146).

TRANSITION FROM THE HOSPITAL TO THE AMBULATORY SETTING

Recommendation

16.14 A structured discharge plan should be tailored to the individual with diabetes. **B**

A structured discharge plan tailored to the individual may reduce the length of hospital stay and readmission rates and increase satisfaction with the hospital experience (147). Multiple strategies are key, including diabetes self-management education prior to discharge, diabetes medication reconciliation with attention to access, and scheduled virtual and/or face-to-face follow-up visits after discharge. Discharge planning should begin at admission and be updated as individual needs change (148,149).

The transition from the acute care setting presents risks for all people with diabetes. Individuals may be discharged to varied settings, including home (with or without visiting nurse services), assisted living, rehabilitation, or skilled nursing facilities. For individuals discharged to home or assisted living, the optimal discharge plan will need to consider diabetes type and severity, effects of the illness on blood glucose levels, and the individual's circumstances, capabilities, and preferences (21,150,151). See Section 13, "Older Adults," for more information.

An outpatient follow-up visit with the primary care clinician, endocrinologist, or diabetes care and education specialist within 1 month of discharge is advised for all individuals experiencing hyperglycemia and/or hypoglycemia in the hospital. If glycemic medications are changed or glucose management is not optimal at discharge, an earlier appointment (in 1–2 weeks) is preferred, and frequent contact may be needed to avoid hyperglycemia and hypoglycemia. A discharge algorithm for glycemic medication adjustment, based on admission A1C, diabetes medications before admission, and insulin usage during hospitalization was found useful to guide treatment decisions and significantly improve A1C after discharge (4).

Clear communication with outpatient health care professionals directly or via hospital discharge summaries facilitates safe transitions to outpatient care. Providing information regarding the root cause of hyperglycemia (or the plan for determining the cause), related complications and comorbidities, and recommended treatments can assist outpatient health care professionals as they assume ongoing care.

The Agency for Healthcare Research and Quality recommends that, at a minimum, discharge plans include the following (152):

Medication Reconciliation

- Home and hospital medications must be cross-checked to ensure that no chronic medications are stopped and to ensure the safety of new and old prescriptions.
- Prescriptions for new or changed medication should be filled and reviewed with the individual and care partners at or before discharge.

Structured Discharge Communication

- Information on medication changes, pending tests and studies, and follow-up needs must be accurately and promptly communicated to outpatient health care professionals.
- Discharge summaries should be transmitted to the primary care clinician as soon as possible after discharge.
- Scheduling follow-up appointments prior to discharge with people with diabetes agreeing to the time and place increases the likelihood that they will attend.

It is recommended that the following areas of knowledge be reviewed and addressed before hospital discharge:

- Identification of the health care professionals who will provide diabetes care after discharge.
- Level of understanding related to the diabetes diagnosis, glucose monitoring, home glucose goals, and when to call a health care professional.
- Definition, recognition, treatment, and prevention of hyperglycemia and hypoglycemia.
- Information on making healthy food choices at home and referral to an outpatient registered dietitian nutritionist or diabetes care and education specialist to guide individualization of the meal plan, if needed.
- When and how to take blood glucose-lowering medications, including insulin administration and noninsulin injectables.
- Sick-day management (21,151).
- Proper use and disposal of diabetes supplies, e.g., insulin pen, pen needles, syringes, and lancets.

People with diabetes must be provided with appropriate durable medical equipment, medications, supplies (e.g., blood glucose test strips or CGM

sensors), prescriptions, and appropriate education at the time of discharge to avoid a potentially dangerous hiatus in care.

PREVENTING ADMISSIONS AND READMISSIONS

In people with diabetes, the hospital readmission rate is between 14% and 20%, which is nearly twice that in people without diabetes (148,153). This may result in increased diabetes distress and has significant financial implications. Of people with diabetes who are hospitalized, 30% have two or more hospital stays, and these admissions account for over 50% of hospital costs for diabetes (154). Factors contributing to readmission include male sex, longer duration of prior hospitalization, number of previous hospitalizations, number and severity of comorbidities, and lower socioeconomic and/or educational status; factors that may reduce readmission rates include scheduled home health visits and timely ambulatory follow-up care (148,153). While there is no standard to prevent readmissions, several successful strategies have been reported that identify high-risk individuals and offer some possible solutions (148). These include reaching out to people with ketosis-prone diabetes (155), insulin treatment of individuals with admission A1C >9% (>75 mmol/mol) (156), and the use of a transitional care model (157). For people with diabetic kidney disease, collaborative person-centered medical homes may decrease risk-adjusted readmission rates (158).

Age is also an important risk factor in hospitalization and readmission among people with diabetes (refer to Section 13, "Older Adults," for detailed criteria). Successful proactive care transitions from inpatient to outpatient is a key strategy for preventing readmission.

References

- Seisa MO, Saadi S, Nayfeh T, et al. A systematic review supporting the Endocrine Society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures. *J Clin Endocrinol Metab* 2022;107:2139–2147
- ElSayed NA, Aleppo G, Aroda VR, et al. American Diabetes Association. 16. Diabetes care in the hospital: *Standards of Care in Diabetes—2023*. *Diabetes Care* 2023;46(Suppl. 1):S267–S278
- Pasquel FJ, Gomez-Huelgas R, Anzola I, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. *Diabetes Care* 2015;38:e202–e203
- Umpierrez GE, Reyes D, Smiley D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. *Diabetes Care* 2014;37:2934–2939
- Carpenter DL, Gregg SR, Xu K, Buchman TG, Coopersmith CM. Prevalence and impact of unknown diabetes in the ICU. *Crit Care Med* 2015;43:e541–e550
- Nanayakkara N, Nguyen H, Churilov L, et al. Inpatient HbA1c testing: a prospective observational study. *BMJ Open Diabetes Res Care* 2015;3:e000113
- Nassar CM, Montero A, Magee MF. Inpatient diabetes education in the real world: an overview of guidelines and delivery models. *Curr Diab Rep* 2019;19:103
- Garg R, Schuman B, Bader A, et al. Effect of preoperative diabetes management on glycemic control and clinical outcomes after elective surgery. *Ann Surg* 2018;267:858–862
- van den Boom W, Schroeder RA, Manning MW, Setji TL, Fiestan GO, Dunson DB. Effect of A1C and glucose on postoperative mortality in noncardiac and cardiac surgeries. *Diabetes Care* 2018;41:782–788
- Setji T, Hopkins TJ, Jimenez M, et al. Rationalization, development, and implementation of a preoperative diabetes optimization program designed to improve perioperative outcomes and reduce cost. *Diabetes Spectr* 2017;30:217–223
- Okabayashi T, Shima Y, Sumiyoshi T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. *Diabetes Care* 2014;37:1516–1524
- Institute of Medicine. *Preventing Medication Errors*. Aspden P, Wolcott J, Bootman JL, Cronenwett LR, Eds. Washington, DC, National Academies Press, 2007
- Sly B, Russell AW, Sullivan C. Digital interventions to improve safety and quality of inpatient diabetes management: a systematic review. *Int J Med Inform* 2022;157:104596
- Nguyen M, Jankovic I, Kalesinskas L, Baiocchi M, Chen JH. Machine learning for initial insulin estimation in hospitalized patients. *J Am Med Assoc* 2021;328:2212–2219
- Akiboye F, Sihre HK, Al Mulhem M, Rayman G, Nirantharakumar K, Adderley NJ. Impact of diabetes specialist nurses on inpatient care: a systematic review. *Diabet Med* 2021;38:e14573
- Wang YJ, Seggelke S, Hawkins RM, et al. Impact of glucose management team on outcomes of hospitalization in patients with type 2 diabetes admitted to the medical service. *Endocr Pract* 2016;22:1401–1405
- Bansal V, Motalib A, Pawar TK, et al. Inpatient diabetes management by specialized diabetes team versus primary service team in non-critical care units: impact on 30-day readmission rate and hospital cost. *BMJ Open Diabetes Res Care* 2018;6:e000460
- Ostling S, Wyckoff J, Ciarkowski SL, et al. The relationship between diabetes mellitus and 30-day readmission rates. *Clin Diabetes Endocrinol* 2017;3:3
- Rushakoff RJ, Sullivan MM, MacMaster HW, et al. Association between a virtual glucose management service and glycemic control in hospitalized adult patients: an observational study. *Ann Intern Med* 2017;166:621–627
- Magee MF, Baker KM, Bardsley JK, Wesley D, Smith KM. Diabetes to go-inpatient: pragmatic lessons learned from implementation of technology-enabled diabetes survival skills education within nursing unit workflow in an urban, tertiary care hospital. *Jt Comm J Qual Patient Saf* 2021;47:107–119
- Pinkhasova D, Swami JB, Patel N, et al. Patient understanding of discharge instructions for home diabetes self-management and risk for hospital readmission and emergency department visits. *Endocr Pract* 2021;27:561–566
- Society of Hospital Medicine. Glycemic control for hospitalists. Accessed 21 August 2023. Available from <https://www.hospitalmedicine.org/clinical-topics/glycemic-control/>
- Arnold P, Scheurer D, Dake AW, et al. Hospital guidelines for diabetes management and the Joint Commission-American Diabetes Association Inpatient Diabetes Certification. *Am J Med Sci* 2016;351:333–341
- Association of British Diabetologists. Joint British Diabetes Societies (JBDS) for Inpatient Care Group. Accessed 21 August 2023. Available from <https://abcd.care/jbds-ip>
- Agiostatridou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA_{1c} for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. *Diabetes Care* 2017;40:1622–1630
- Cardona S, Gomez PC, Vellanki P, et al. Clinical characteristics and outcomes of symptomatic and asymptomatic hypoglycemia in hospitalized patients with diabetes. *BMJ Open Diabetes Res Care* 2018;6:e000607
- Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359–1367
- Finfer S, Chittock DR, Su SY, et al.; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360:1283–1297
- Kansagara D, Fu R, Freeman M, Wolf F, Helfand M. Intensive insulin therapy in hospitalized patients: a systematic review. *Ann Intern Med* 2011;154:268–282
- Sathya B, Davis R, Taveira T, Whitlatch H, Wu WC. Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. *Diabetes Res Clin Pract* 2013;102:8–15
- Umpierrez G, Cardona S, Pasquel F, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. *Diabetes Care* 2015;38:1665–1672
- Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. *Endocr Pract* 2004;10(Suppl. 2):21–33
- Magaji V, Nayak S, Donihi AC, et al. Comparison of insulin infusion protocols targeting 110–140 mg/dL in patients after cardiac surgery. *Diabetes Technol Ther* 2010;14:1013–1017
- Flory JH, Aleman JO, Furst J, Seley JJ. Basal insulin use in the non-critical care setting: is fasting hypoglycemia inevitable or preventable? *J Diabetes Sci Technol* 2014;8:427–428

35. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Diabetes Care* 2023;46:e151–e199
36. DuBois JA, Slingerland RJ, Fokkert M, et al. Bedside glucose monitoring—is it safe? A new, regulatory-compliant risk assessment evaluation protocol in critically ill patient care settings. *Crit Care Med* 2017;45:567–574
37. Zhang R, Isakow W, Kollef MH, Scott MG. Performance of a modern glucose meter in ICU and general hospital inpatients: 3 years of real-world paired meter and central laboratory results. *Crit Care Med* 2017;45:1509–1514
38. Misra S, Avari P, Lumb A, et al. How can point-of-care technologies support in-hospital diabetes care? *J Diabetes Sci Technol* 2023;17:509–516
39. Fortmann AL, Spierling Bagsic SR, Talavera L, et al. Glucose as the fifth vital sign: a randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting. *Diabetes Care* 2020;43:2873–2877
40. Galindo RJ, Migdal AL, Davis GM, et al. Comparison of the FreeStyle Libre Pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen. *Diabetes Care* 2020;43:2730–2735
41. Galindo RJ, Umpierrez GE, Rushakoff RJ, et al. Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline. *J Diabetes Sci Technol* 2020;14:1035–1064
42. Singh LG, Satyarengga M, Marcano I, et al. Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: the glucose telemetry system, a randomized clinical trial. *Diabetes Care* 2020;43:2736–2743
43. Spanakis EK, Urrutia A, Galindo RJ, et al. Continuous glucose monitoring-guided insulin administration in hospitalized patients with diabetes: a randomized clinical trial. *Diabetes Care* 2022;45:2369–2375
44. Wallia A, Prince G, Touma E, El Muayed M, Seley JJ. Caring for hospitalized patients with diabetes mellitus, hyperglycemia, and COVID-19: bridging the remaining knowledge gaps. *Curr Diab Rep* 2020;20:77
45. Galindo RJ, Aleppo G, Klonoff DC, et al. Implementation of continuous glucose monitoring in the hospital: emergent considerations for remote glucose monitoring during the COVID-19 pandemic. *J Diabetes Sci Technol* 2020;14:822–832
46. Longo RR, Elias H, Khan M, Seley JJ. Use and accuracy of inpatient CGM during the COVID-19 pandemic: an observational study of general medicine and ICU patients. *J Diabetes Sci Technol* 2022;16:1136–1143
47. Davis GM, Spanakis EK, Migdal AL, et al. Accuracy of Dexcom G6 continuous glucose monitoring in non-critically ill hospitalized patients with diabetes. *Diabetes Care* 2021;44:1641–1646
48. Baker M, Musselman ME, Rogers R, Hellman R. Practical implementation of remote continuous glucose monitoring in hospitalized patients with diabetes. *Am J Health Syst Pharm* 2022;79:452–458
49. Wright JJ, Williams AJ, Friedman SB, et al. Accuracy of continuous glucose monitors for inpatient diabetes management. *J Diabetes Sci Technol* 2023;17:1252–1255
50. Bellido V, Freckman G, Perez A, Galindo RJ. Accuracy and potential interferences of continuous glucose monitoring sensors in the hospital. *Endocr Pract* 29:919–927
51. Avari P, Lumb A, Flanagan D, et al. Continuous glucose monitoring within hospital: a scoping review and summary of guidelines from the Joint British Diabetes Societies for Inpatient Care. *J Diabetes Sci Technol* 2023;17:611–624
52. Braithwaite SS, Clark LP, Idrees T, Qureshi F, Soetan OT. Hypoglycemia prevention by algorithm design during intravenous insulin infusion. *Curr Diab Rep* 2018;18:26
53. Dhataria KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. *Nat Rev Dis Primers* 2020;6:40
54. Anis TR, Bourdreau M, Thornton T. Comparing the efficacy of a nurse-driven and a physician-driven diabetes ketoacidosis (DKA) treatment protocol. *Clin Pharmacol* 2021;13:197–202
55. Rao P, Jiang SF, Kipnis P, Patel DM, Katsnelson S, Madani S, Liu VX. Evaluation of outcomes following hospital-wide implementation of a subcutaneous insulin protocol for diabetic ketoacidosis. *JAMA Netw Open* 2022;5:e226417
56. Maynard G, Wesorick DH, O'Malley C; Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. *J Hosp Med* 2008;3(Suppl.):29–41
57. Brown KE, Hertig JB. Determining current insulin pen use practices and errors in the inpatient setting. *Jt Comm J Qual Patient Saf* 2016;42:568–575, AP1–AP7
58. Horne J, Bond R, Sarangarm P. Comparison of inpatient glycemic control with insulin vials versus insulin pens in general medicine patients. *Hosp Pharm* 2015;50:514–521
59. Veronesi G, Poerio CS, Braus A, et al. Determinants of nurse satisfaction using insulin pen devices with safety needles: an exploratory factor analysis. *Clin Diabetes Endocrinol* 2015;1:15
60. Institute for Safe Medication Practices. *ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults*. 2017. Accessed 21 August 2023. Available from <https://www.ismp.org/sites/default/files/attachments/2018-09/ISMP138D-Insulin%20Guideline-090718.pdf>
61. Najmi U, Haque WZ, Ansari U, et al. Inpatient insulin pen implementation, waste, and potential cost savings: a community hospital experience. *J Diabetes Sci Technol* 2021;15:741–747
62. Bueno E, Benitez A, Rufinelli JV, et al. Basal-bolus regimen with insulin analogues versus human insulin in medical patients with type 2 diabetes: a randomized controlled trial in Latin America. *Endocr Pract* 2015;21:807–813
63. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). *Diabetes Care* 2011;34:256–261
64. Colunga-Lozano LE, Gonzalez Torres FJ, Delgado-Figueroa N, et al. Sliding scale insulin for non-critically ill hospitalized adults with diabetes mellitus. *Cochrane Database Syst Rev* 2018;11:CD011296
65. Migdal AL, Fortin-Leung C, Pasquel F, Wang H, Peng L, Umpierrez GE. Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 diabetes: who can slide? *J Hosp Med* 2021;16:462–468
66. Bellido V, Suarez L, Rodriguez MG, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. *Diabetes Care* 2015;38:2211–2216
67. Galindo RJ, Pasquel FJ, Vellanki P, et al. Degludec hospital trial: a randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes. *Diabetes Obes Metab* 2022;24:42–49
68. Pasquel FJ, Lansang MC, Khawaja A, et al. A randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and surgery patients with type 2 diabetes: glargine U300 hospital trial. *Diabetes Care* 2020;43:1242–1248
69. Perez A, Carrasco-Sánchez FJ, González C, et al. Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. *BMJ Open Diabetes Res Care* 2020;8:e001518
70. Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. *Diabetes Care* 2012;35:1970–1974
71. Iyengar R, Franzese J, Gianchandani R. Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis. *Curr Diab Rep* 2018;18:75
72. Shomali ME, Herr DL, Hill PC, Pehlivanova M, Sharretts JM, Magee MF. Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: transition to target study. *Diabetes Technol Ther* 2011;13:121–126
73. Kreider KE, Lien LF. Transitioning safely from intravenous to subcutaneous insulin. *Curr Diab Rep* 2015;15:23
74. Thammakosol K, Sriprapradang C. Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: a randomized controlled trial. *Diabetes Obes Metab* 2023;25:815–822
75. Hsia E, Seggelke S, Gibbs J, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. *J Clin Endocrinol Metab* 2012;97:3132–3137
76. Lim Y, Ohn JH, Jeong J, et al. Effect of the concomitant use of subcutaneous basal insulin and intravenous insulin infusion in the treatment of severe hyperglycemic patients. *Endocrinol Metab (Seoul)* 2022;37:444–454
77. Tripathy PR, Lansang MC. U-500 regular insulin use in hospitalized patients. *Endocr Pract* 2015;21:54–58
78. Lansang MC, Umpierrez GE. Inpatient hyperglycemia management: a practical review for primary medical and surgical teams. *Cleve Clin J Med* 2016;83(Suppl. 1):S34–S43
79. Galindo RJ, Dhataria K, Gomez-Peralta F, Umpierrez GE. Safety and efficacy of inpatient diabetes management with non-insulin agents:

- an overview of international practices. *Curr Diab Rep* 2022;22:237–246
80. Pasquel FJ, Lansang MC, Dhatriya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. *Lancet Diabetes Endocrinol* 2021;9:174–188
81. Umpierrez GE, Gianchandani R, Smiley D, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. *Diabetes Care* 2013;36:3430–3435
82. Fushimi N, Shibuya T, Yoshida Y, Ito S, Hachiya H, Mori A. Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients. *J Diabetes Investig* 2020;11:125–131
83. Fayfman M, Galindo RJ, Rubin DJ, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. *Diabetes Care* 2019;42:450–456
84. Pérez-Belmonte LM, Osuna-Sánchez J, Millán-Gómez M, et al. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study. *Ann Med* 2019;51:252–261
85. Vellanki P, Rasouli N, Baldwin D, et al.; Linagliptin Inpatient Research Group. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicentre randomized clinical trial. *Diabetes Obes Metab* 2019;21:837–843
86. Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. *Lancet Diabetes Endocrinol* 2017;5:125–133
87. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Accessed 21 August 2023. Available from <https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm>
88. Kosiborod MN, Angermann CE, Collins S, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. *Circulation* 2022;146:279–288
89. Tamaki S, Yamada T, Watanabe T, et al. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study [published correction appears in *Circ Heart Fail* 2021;14:e000067]. *Circ Heart Fail* 2021;14:e007048
90. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. *J Am Coll Cardiol* 2022;80:1302–1310
91. Salah HM, Al'Aref SJ, Khan MS, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. *Cardiovasc Diabetol* 2022;21:20
92. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. *Nat Med* 2022;28:568–574
93. Jhund PS, Ponikowski P, Docherty KF, et al. Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. *Circulation* 2021;143:1962–1972
94. U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Accessed 21 August 2023. Available from <https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious>
95. Lake A, Arthur A, Byrne C, Davenport K, Yamamoto JM, Murphy HR. The effect of hypoglycaemia during hospital admission on health-related outcomes for people with diabetes: a systematic review and meta-analysis. *Diabet Med* 2019;36:1349–1359
96. Garg R, Hurwitz S, Turchin A, Trivedi A. Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hospitalized patients. *Diabetes Care* 2013;36:1107–1110
97. Ilcewicz HN, Hennessey EK, Smith CB. Evaluation of the impact of an inpatient hyperglycemia protocol on glycemic control. *J Pharm Pharm Sci* 2019;22:85–92
98. Sinha Gregory N, Seley JJ, Gerber LM, Tang C, Brillon D. Decreased rates of hypoglycemia following implementation of a comprehensive computerized insulin order set and titration algorithm in the inpatient setting. *Hosp Pract (1995)* 2016;44:260–265
99. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. *Diabetes Care* 2009;32:1119–1131
100. Akirov A, Grossman A, Shochat T, Shimon I. Mortality among hospitalized patients with hypoglycemia: insulin related and noninsulin related. *J Clin Endocrinol Metab* 2017;102:416–424
101. Amori RE, Pittas AG, Siegel RD, et al. Inpatient medical errors involving glucose-lowering medications and their impact on patients: review of 2,598 incidents from a voluntary electronic error-reporting database. *Endocr Pract* 2008;14:535–542
102. Alwan D, Chipps E, Yen PY, Dungan K. Evaluation of the timing and coordination of prandial insulin administration in the hospital. *Diabetes Res Clin Pract* 2017;131:18–32
103. Korytkowski M, Dinardo M, Donihi AC, Bigi L, Devita M. Evolution of a diabetes inpatient safety committee. *Endocr Pract* 2006;12(Suppl. 3):91–99
104. Hung AM, Siew ED, Wilson OD, et al. Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury. *Diabetes Care* 2018;41:503–512
105. Maynard G, Kulasa K, Ramos P, et al. Impact of a hypoglycemia reduction bundle and a systems approach to inpatient glycemic management. *Endocr Pract* 2015;21:355–367
106. Milligan PE, Bocox MC, Pratt E, Hoehner CM, Krettek JE, Dunagan WC. Multifaceted approach to reducing occurrence of severe hypoglycemia in a large healthcare system. *Am J Health Syst Pharm* 2015;72:1631–1641
107. Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nat Rev Endocrinol* 2016;12:222–232
108. Dagogo-Jack S. Hypoglycemia in type 1 diabetes mellitus: pathophysiology and prevention. *Treat Endocrinol* 2004;3:91–103
109. Rickels MR. Hypoglycemia-associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. *Ann N Y Acad Sci* 2019;1454:68–79
110. Dendy JA, Chockalingam V, Tirumalasetty NN, et al. Identifying risk factors for severe hypoglycemia in hospitalized patients with diabetes. *Endocr Pract* 2014;20:1051–1056
111. Ulmer BJ, Kara A, Mariash CN. Temporal occurrences and recurrence patterns of hypoglycemia during hospitalization. *Endocr Pract* 2015;21:501–507
112. Shah BR, Walji S, Kiss A, James JE, Lowe JM. Derivation and validation of a risk-prediction tool for hypoglycemia in hospitalized adults with diabetes: the Hypoglycemia During Hospitalization (HyDHo) score. *Can J Diabetes* 2019;43:278–282.e1
113. Mathioudakis NN, Everett E, Routh S, et al. Development and validation of a prediction model for insulin-associated hypoglycemia in non-critically ill hospitalized adults. *BMJ Open Diabetes Res Care* 2018;6:e000499
114. Curl M, Dinardo M, Noschese M, Korytkowski MT. Menu selection, glycaemic control and satisfaction with standard and patient-controlled consistent carbohydrate meal plans in hospitalised patients with diabetes. *Qual Saf Health Care* 2010;19:355–359
115. Drincic AT, Knezevich JT, Akkireddy P. Nutrition and hyperglycemia management in the inpatient setting (meals on demand, parenteral, or enteral nutrition). *Curr Diab Rep* 2017;17:59
116. Korytkowski M, Draznin B, Drincic A. Food, fasting, insulin, and glycemic control in the hospital. In *Managing Diabetes and Hyperglycemia in the Hospital Setting*. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, p. 70–83
117. Mabrey ME, Setji TL. Patient self-management of diabetes care in the inpatient setting: pro. *J Diabetes Sci Technol* 2015;9:1152–1154
118. Shah AD, Rushakoff RJ. Patient self-management of diabetes care in the inpatient setting: con. *J Diabetes Sci Technol* 2015;9:1155–1157
119. Flanagan D, Dhatriya K; Joint British Diabetes Societies (JBDS) for Inpatient Care group and Guidelines writing group. Self-management of diabetes in hospital: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. *Diabet Med* 2018;35:992–996
120. Umpierrez GE, Klonoff DC. Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital. *Diabetes Care* 2018;41:1579–1589
121. Houlden RL, Moore S. In-hospital management of adults using insulin pump therapy. *Can J Diabetes* 2014;38:126–133

122. Korytkowski MT, Salata RJ, Koerbel GL, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. *Diabetes Care* 2009;32:594–596
123. Hsia E, Seggelke SA, Gibbs J, Rasouli N, Draznin B. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. *Nutr Clin Pract* 2011;26:714–717
124. Oliveira G, Abuín J, López R, et al. Regular insulin added to total parenteral nutrition vs subcutaneous glargine in non-critically ill diabetic inpatients, a multicenter randomized clinical trial: INSUPAR trial. *Clin Nutr* 2020;39:388–394
125. Pichardo-Lowden AR, Fan CY, Gabbay RA. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. *Endocr Pract* 2011;17:249–260
126. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. *Endocr Pract* 2006;12:358–362
127. Narwani V, Swafe L, Stavra C, Dhataria K. How frequently are bedside glucose levels measured in hospital inpatients on glucocorticoid treatment? *Clin Med (Lond)* 2014;14:327–328
128. Roberts A, James J. Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. *Diabet Med* 2018;35:1011–1017
129. Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-induced hyperglycemia. *Am J Med Sci* 2013;345:274–277
130. Seggelke SA, Gibbs J, Draznin B. Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. *J Hosp Med* 2011;6:175–176
131. Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy. *Diabetes Technol Ther* 2014;16:874–879
132. Cheng YC, Guerra Y, Morkos M, et al. Insulin management in hospitalized patients with diabetes mellitus on high-dose glucocorticoids: management of steroid-exacerbated hyperglycemia. *PLoS One* 2021;16:e0256682
133. Bajaj MA, Zale AD, Morgenlander WR, Abusamaan MS, Mathioudakis N. Insulin dosing and glycemic outcomes among steroid-treated hospitalized patients. *Endocr Pract* 2022;28:774–779
134. Gianchandani R, Dubois E, Alexanian S, Rushakoff R. Preoperative, intraoperative, and postoperative glucose management. In *Managing Diabetes and Hyperglycemia in the Hospital Setting*. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, p. 129–144
135. Duggan EW, Carlson K, Umpierrez GE. Perioperative hyperglycemia management: an update. *Anesthesiology* 2017;126:547–560
136. Todd LA, Vigersky RA. Evaluating perioperative glycemic control of non-cardiac surgical patients with diabetes. *Mil Med* 2021;186:e867–e872
137. Bellon F, Solà I, Gimenez-Perez G, et al. Perioperative glycaemic control for people with diabetes undergoing surgery. *Cochrane Database Syst Rev* 2023;8:CD007315
138. Perez-Guzman MC, Duggan E, Gibanica S, et al. Continuous glucose monitoring in the operating room and cardiac intensive care unit. *Diabetes Care* 2021;44:e50–e52
139. Demma LJ, Carlson KT, Duggan EW, Morrow JG 3rd, Umpierrez G. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes. *J Clin Anesth* 2017;36:184–188
140. Harrison VS, Rustico S, Palladino AA, Ferrara C, Hawkes CP. Glargine co-administration with intravenous insulin in pediatric diabetic ketoacidosis is safe and facilitates transition to a subcutaneous regimen. *Pediatr Diabetes* 2017;18:742–748
141. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care* 2009;32:1335–1343
142. Vellanki P, Umpierrez GE. Diabetic ketoacidosis: a common debut of diabetes among African Americans with type 2 diabetes. *Endocr Pract* 2017;23:971–978
143. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. *Cochrane Database Syst Rev* 2016;2016:CD011281
144. Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. *J Clin Endocrinol Metab* 2008;93:1541–1552
145. Karajgikar ND, Manroa P, Acharya R, et al. Addressing pitfalls in management of diabetic ketoacidosis with a standardized protocol. *Endocr Pract* 2019;25:407–412
146. Moghissi E, Inzucchi S. The evolution of glycemic control in the hospital setting. In *Managing Diabetes and Hyperglycemia in the Hospital Setting*. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, pp. 1–10
147. Shepperd S, Lannin NA, Clemson LM, McCluskey A, Cameron ID, Barras SL. Discharge planning from hospital to home. *Cochrane Database Syst Rev* 2013;1:CD000313
148. Gregory NS, Seley JJ, Dargar SK, Galla N, Gerber LM, Lee JI. Strategies to prevent readmission in high-risk patients with diabetes: the importance of an interdisciplinary approach. *Curr Diab Rep* 2018;18:54
149. Rubin DJ, Shah AA. Predicting and preventing acute care re-utilization by patients with diabetes. *Curr Diab Rep* 2021;21:34
150. Rinaldi A, Snider M, James A, et al. The impact of a diabetes transitions of care clinic on hospital utilization and patient care. *Ann Pharmacother* 2023;57:127–132
151. Patel N, Swami J, Pinkhasova D, et al. Sex differences in glycemic measures, complications, discharge disposition, and postdischarge emergency room visits and readmission among non-critically ill, hospitalized patients with diabetes. *BMJ Open Diabetes Res Care* 2022;10:e002722
152. Agency for Healthcare Research and Quality. Patient Safety Network – Readmissions and adverse events after discharge, 2019. Accessed 22 August 2023. Available from <https://psnet.ahrq.gov/primer.aspx?primerID=11>
153. Rubin DJ. Hospital readmission of patients with diabetes. *Curr Diab Rep* 2015;15:17
154. Jiang HJ, Stryer D, Friedman B, Andrews R. Multiple hospitalizations for patients with diabetes. *Diabetes Care* 2003;26:1421–1426
155. Maldonado MR, D’Amico S, Rodriguez L, Iyer D, Balasubramanyam A. Improved outcomes in indigent patients with ketosis-prone diabetes: effect of a dedicated diabetes treatment unit. *Endocr Pract* 2003;9:26–32
156. Wu EQ, Zhou S, Yu A, et al. Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital. *Hosp Pract (1995)* 2012;40:40–48
157. Hirschman KB, Bixby MB. Transitions in care from the hospital to home for patients with diabetes. *Diabetes Spectr* 2014;27:192–195
158. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care* 2022;45:3075–3090